3017 T3D2975 Perhexiline Perhexiline is only found in individuals that have used or taken this drug. It is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis. [PubChem]Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. 6621-47-2 4746 C19H35N 277.276950 White powder. 0.0608 mg/L Well absorbed (>80%) from the gastrointestinal tract following oral administration. Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. The principal metabolites of perhexiline in man are monohydroxyperhexiline (which is excreted, in part, conjugated with glucuronic acid) and dihydroxyperhexiline that accounts for a relatively small proportion of the total metabolites. Two unidentified metabolites have also been found in the faeces. The pharmacological activity of the metabolites is not known. Hydroxylation of perhexiline is controlled by cytochrome P450 2D6 (CY P450 2D6). Half Life: Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days. LD50: 2150 mg/kg (Oral, Rat) (A308) LD50: 2641 mg/kg (Oral, Mouse) (A308) No indication of carcinogenicity to humans (not listed by IARC). For the management of severe angina pectoris. Short term adverse effects include nausea, transient dizziness, hypoglycaemia in diabetic patients, and torsade de pointes (rare). 2009-07-21T20:28:18Z 2014-12-24T20:25:54Z Perhexiline 35553 Perhexiline DB01074 true C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1 C19H35N InChI=1/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2 InChIKey=CYXKNKQEMFBLER-UHFFFAOYNA-N 277.4879 277.276950125 Exogenous Solid 6.2 HMDB15207 CHEMBL75880 4584 <p>Stephen W. Horgan, Frank P. Palopoli, Edward J. Schwoegler, &#8220;Process for preparing 2-(2,2-dicyclohexylethyl)piperidine.&#8221; U.S. Patent US4069222, issued August, 1950.</p>